Steven J. Bensinger

Professor of Immunology and Immune Therapeutics and Cancer Biology

Chair, Department of Immunology and Immune Therapeutics

Image of Steven J. Bensinger
Is this your profile? Click to edit

Overview

Steven Bensinger, VMD, PhD, serves as Chair of the Department of Immunology and Immune Therapeutics. He previously served at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), where he held the positions of Professor and Vice Chair for Academic Personnel in the Department of Microbiology, Immunology, and Molecular Genetics, as well as Director of the UCLA Lipidomics Laboratory. Since 2008, Dr. Bensinger has performed innovative research and pioneered advanced analytical methods to elucidate how lipid metabolism influences innate and adaptive immunity. Continuously funded by the NIH for the past 17 years, he has earned notable professional honors, including the Sontag Foundation Distinguished Scientist Award, the UCLA Life Sciences Excellence Award for Outstanding Research, and the Sherie and Donald Morrison Endowed Chair in Immunology. His leadership roles have included serving as Director of the Inflammation, Immunology, Infection, and Transplantation (I3T) Research Theme at the David Geffen School of Medicine and Director of Shared Resources at the Jonsson Comprehensive Cancer Center at UCLA.

Research Funding

  • Targeting host lipid metabolism to limit tissue damage in necrotizing fasciitis
    NIH · R01AI175831 · Feb 1, 2023 – Jan 31, 2028 · Role: Principal Investigator
  • CDKN2A couples lipid metabolism to ferroptosis in glioblastoma
    NIH · R01NS121319 · Apr 1, 2021 – Jan 31, 2026 · Role: Co-Principal Investigator
  • Investigating the impact of a fatty acid-cRel inflammatory circuit in atherosclerosis
    NIH · R01HL157710 · Apr 1, 2021 – Mar 31, 2025 · Role: Principal Investigator
  • Understanding the influence of SREBP signaling on CD4 T helper cell biology
    NIH · R01AI122282 · Nov 10, 2015 – Oct 31, 2020 · Role: Principal Investigator
  • Investigating the crosstalk between lipid metabolism and HIV
    NIH · R21HL126556 · Sep 17, 2014 – Jun 30, 2016 · Role: Principal Investigator
  • Determining the Impact of SREBP on Adaptive Immunity
    NIH · R01AI093768 · Apr 1, 2012 – Mar 31, 2017 · Role: Principal Investigator
  • Apoptosis in the Generation of T-cell Memory
    NIH · K01RR021975 · Sep 30, 2005 – Jun 30, 2010 · Role: Principal Investigator

Publications

  • Psychological stress increases skin infection through the action of TGFβ to suppress immune-acting fibroblasts. Sci Immunol. 2025 04 11; 10(106):eads0519.. View in PubMed
  • Targeting SCD triggers lipotoxicity of cancer cells and enhances anti-tumor immunity in breast cancer brain metastasis mouse models. Commun Biol. 2025 Apr 04; 8(1):562.. View in PubMed
  • Disrupting cholesterol homeostasis in T cells boosts antitumour responses. Nat Metab. 2025 Mar; 7(3):441-443.. View in PubMed
  • A clinical drug candidate that triggers non-apoptotic cancer cell death. Res Sq. 2025 Feb 11.. View in PubMed
  • The metabolic cofactor Coenzyme A enhances alternative macrophage activation via MyD88-linked signaling. bioRxiv. 2025 Jan 20.. View in PubMed
  • Pro-inflammatory macrophage activation does not require inhibition of oxidative phosphorylation. EMBO Rep. 2025 02; 26(4):982-1002.. View in PubMed
  • Flow-mediated modulation of the endothelial cell lipidome. Front Physiol. 2024; 15:1431847.. View in PubMed
  • Flow-Mediated Modulation of the Endothelial Cell Lipidome. bioRxiv. 2024 Jun 15.. View in PubMed
  • IL-4 Licenses B Cell Activation Through Cholesterol Synthesis. bioRxiv. 2024 May 15.. View in PubMed
  • Pro-inflammatory macrophage activation does not require inhibition of mitochondrial respiration. bioRxiv. 2024 May 14.. View in PubMed